All In Biotech

Drug Trial Radar · NCT03181893

A Study In Adults With Moderate To Severe Dermatomyositis

A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS

Last checked: Nov 20, 2026Latest source record: Sep 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

75

Actual

Start

Jan 23, 2018

Primary completion

May 27, 2022

Study completion Nov 28, 2022

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jun 9, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Study looking at Investigational drug and Placebo administered to adult Patients with moderate to severe Dermatomyositis

Conditions

  • Dermatomyositis

Interventions

  • PF-06823859 lowDrug

    A humanized immunoglobulin neutralizing antibody

  • Placebo ArmDrug

    Placebo contains histidine, sucrose, PS80, ethylene diamine, and triacetic acid

  • PF-06823859 highDrug

    A humanized immunoglobulin neutralizing antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Score at Week 12 (Stage 1, Stage 2 and Amended Stage 2)Time frame: Baseline and Week 12
  2. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE) (Stage 3)Time frame: Up to Week 40
  3. Number of Participants With Clinically Significant Laboratory Abnormalities (Stage 3)Time frame: Up to Week 40
  4. Number of Participants With Vital Sign Abnormalities (Stage 3)Time frame: Baseline up to Week 40
  5. Number of Participants With Electrocardiogram (ECG) Abnormalities (Stage 3)Time frame: Baseline up to Week 40

Locations

41 sites in 5 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • The University of Alabama at Birmingham

    Birmingham, Alabama

  • The University of Alabama at Birmingham

    Birmingham, Alabama

  • Mayo Clinic Arizona Research Pharmacy

    Phoenix, Arizona

  • Mayo Clinic

    Scottsdale, Arizona

  • Attune Health Research Inc.

    Beverly Hills, California

  • Freidenrich Center for Translational Research at Stanford University

    Palo Alto, California

  • Mayo Clinic Florida

    Jacksonville, Florida

  • University Of Miami Hospital

    Miami, Florida

  • University of Miami Hospital Clinical Translational Research Site (Infusion site)

    Miami, Florida

  • KU Clinical Research Center - Clinical and Translational Science Unit (CTSU)

    Fairway, Kansas

  • The University of Kansas Medical Center

    Kansas City, Kansas

  • Johns Hopkins Bayview Medical Center

    Baltimore, Maryland

  • Brigham and Women's Hospital - ACC

    Boston, Massachusetts

  • Brigham and Women's Hospital - CTC

    Boston, Massachusetts

  • Brigham and Women's Hospital - CTH

    Boston, Massachusetts

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Clinical Research Unit (CRU)

    Minneapolis, Minnesota

  • Department of Medicine Division of Rheumatic and Autoimmune Disease

    Minneapolis, Minnesota

  • Lillehei Clinical Research Unit (LCRU)

    Minneapolis, Minnesota

  • University of Minnesota Health Rheumatology Clinic

    Minneapolis, Minnesota

  • University of Minnesota, Department of Dermatology

    Minneapolis, Minnesota

  • Center for Outpatient Health

    St Louis, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • New York University School of Medicine

    New York, New York

  • NYU Langone Health Clinical Research Center

    New York, New York

  • Mount Sinai Doctors Dermatology

    New York, New York

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • OHSU, Center for Health and Healing CHH2

    Portland, Oregon

  • Oregon Clinical & Translational Research Institute

    Portland, Oregon

  • Oregon Health & Science University

    Portland, Oregon

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • University of Utah MidValley Dermatology

    Murray, Utah

  • Center for Clinical & Translational Science

    Salt Lake City, Utah

  • Universitaetsklinikum Tuebingen

    Tübingen, Germany

  • University of Debrecen

    Debrecen, Hajdú-Bihar, Hungary

  • Nova Reuma spolka partnerska

    Bialystok, Poland

  • Centrum Medyczne Plejady

    Krakow, Poland

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.